We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52M
AUM Growth
-$6.16B
Cap. Flow
-$249M
Cap. Flow %
-4,517.93%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
PGNY icon
Progyny
PGNY
+$22.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
51
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$33.2K 0.6%
1,896,300
+478,000
+34% +$7.5M
PCVX icon
52
Vaxcyte
PCVX
$7.76B
$32.9K 0.6%
1,513,659
– –
ACRS icon
53
Aclaris Therapeutics
ACRS
$723M
$32.5K 0.59%
2,325,500
+745,600
+47% +$10.4M
IOVA icon
54
Iovance Biotherapeutics
IOVA
$2.05B
$30.9K 0.56%
2,798,441
-3,834,565
-58% -$50.3M
VRNA
55
DELISTED
Verona Pharma
VRNA
$23.9K 0.43%
5,694,841
– –
SCPH
56
DELISTED
scPharmaceuticals
SCPH
$23.1K 0.42%
4,797,148
– –
BIIB icon
57
Biogen
BIIB
$31.9B
$22.8K 0.41%
111,600
-6,300
-5% -$1.29M
TELA icon
58
TELA Bio
TELA
$30.4M
$21.2K 0.38%
3,027,542
– –
PASG icon
59
Passage Bio
PASG
$14.9M
$21.1K 0.38%
446,600
+80,000
+22% +$3.74M
DBTX
60
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$20.8K 0.38%
4,945,192
– –
NPCE icon
61
Neuropace
NPCE
$494M
$19.9K 0.36%
4,012,281
– –
RXST icon
62
RxSight
RXST
$253M
$19.5K 0.35%
1,383,500
– –
MGTX icon
63
MeiraGTx Holdings
MGTX
$1.06B
$18.9K 0.34%
2,501,618
-795,048
-24% -$7.71M
TVTX icon
64
Travere Therapeutics
TVTX
$5.17B
$18.7K 0.34%
+772,200
New +$19.4M
PGNY icon
65
Progyny
PGNY
$2.46B
$18.2K 0.33%
+625,000
New +$22.4M
GILD icon
66
Gilead Sciences
GILD
$166B
$17.8K 0.32%
287,600
– –
ALXO icon
67
ALX Oncology
ALXO
$266M
$17.7K 0.32%
2,186,269
+1,564,569
+252% +$17M
IONS icon
68
Ionis Pharmaceuticals
IONS
$9.07B
$16.8K 0.3%
+453,400
New +$17.1M
IVVD icon
69
Invivyd
IVVD
$171M
$16.6K 0.3%
5,056,000
– –
QURE icon
70
uniQure
QURE
$2.71B
$16.3K 0.3%
874,849
-44,400
-5% -$706K
GHRS icon
71
GH Research
GHRS
$1.9B
$16.2K 0.29%
1,622,060
+193,328
+14% +$2.51M
RAPT
72
DELISTED
RAPT Therapeutics
RAPT
$15.8K 0.29%
108,300
+63,137
+140% +$8.41M
VTYX
73
DELISTED
Ventyx Biosciences
VTYX
$15.8K 0.29%
1,289,280
– –
AMGN icon
74
Amgen
AMGN
$213B
$13.9K 0.25%
57,100
– –
BLU
75
DELISTED
BELLUS Health Inc.
BLU
$13.4K 0.24%
1,454,800
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52M, down 100% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $249M in Q2 2022, closing 15 positions and reducing 36 holdings. Its most notable exit was DexCom, an estimated $76.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Progyny worth $18.2K.

  • OrbiMed's largest Q2 2022 buy was Progyny: 625,000 shares worth $18.2K.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52M portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 100% quarter-over-quarter to $5.52M.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.